Measurable (or minimal) residual disease (MRD) in multiple myeloma (MM) refers to low
levels of myeloma cells detectable using advanced diagnostics. MRD testing is evolving …

Positron emission tomography (PET) is an imaging modality used for the noninvasive
assessment of tumor staging and response to therapy. PET with 18F labeled …

While the prognostic role of immunoglobulin heavy chain locus (IGH) rearrangement in
minimal residual disease (MRD) in pediatric B-acute lymphoblastic leukemia (B-ALL) has …

Bone marrow (BM) assessment of minimal residual disease (MRD) is prognostic for survival
in multiple myeloma (MM). BM is still hypocellular at month 1 post CAR-T, thus the value of …

Simple Summary Patients who are diagnosed with multiple myeloma are given an initial
sequence of treatments that usually, for those who are young and fit enough, includes high …

The diagnosis of multiple myeloma (MM) is based on a wide range of features (“CRAB
criteria”) and includes hypercalcemia (C), renal failure (R), anemia (A), and the presence of …

Advances in morphological and functional imaging have led to superior detection of early
bone disease, bone marrow infiltration, paramedullary and extramedullary involvement in …

Autologous stem cell transplantation (ASCT) remains the mainstay of the treatment in newly
diagnosed transplant-eligible multiple myeloma (MM) patients. This retrospective study was …

Despite significant advancements in multiple myeloma (MM) treatment in recent years, most
patients will eventually develop resistance or experience relapse. Matrine, a primary active …

MRD transcends traditional response assessments by providing a window into disease-
treatment interaction over time. As a strong patient-level surrogate, MRD has limited current …